newsfilter
← Latest News
PR Newswire·

Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication

  • Johnson & Johnson submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval of CAPLYTA (lumateperone) for treating manic or mixed episodes associated with bipolar I disorder in adults.
  • The submission is supported by two positive Phase 3 studies (Study 451 & Study 452) showing CAPLYTA significantly reduced manic symptoms versus placebo as early as Day 3 with improvement sustained through Week 3.
  • If approved, this indication would mark the fifth approved use of CAPLYTA in adults, following existing approvals for bipolar depression, schizophrenia, & major depressive disorder.
  • The pivotal studies were randomized, double-blind, & placebo-controlled trials of once-daily CAPLYTA 42 mg in adults with manic episodes, with or without mixed features.
  • CAPLYTA is currently not approved for the treatment of manic or mixed episodes associated with bipolar I disorder but is approved as monotherapy or adjunctive therapy for bipolar depression, & as adjunctive therapy for major depressive disorder.
  • The drug has an established safety profile with low discontinuation rates, though it carries warnings regarding increased mortality in elderly patients with dementia-related psychosis & suicidal thoughts in young adults.
  • Common side effects include sleepiness, dizziness, nausea, dry mouth, fatigue, & diarrhea, while serious risks include stroke, neuroleptic malignant syndrome, tardive dyskinesia, & metabolic changes.
Company
Johnson & Johnson
Keywords
Johnson & Johnson